Genmab Launches $97-Per-Share Tender Offer for Merus

Reuters10-21
Genmab Launches $97-Per-Share Tender Offer for Merus

Genmab A/S has launched a cash tender offer, through its wholly owned subsidiary Genmab Holding II B.V., to acquire all issued and outstanding common shares of Merus N.V. for $97.00 per share. The offer follows a previously announced agreement between the companies. The transaction is not contingent on financing but is subject to certain other conditions. The offer is set to expire at 5:00 p.m. New York City time on December 11, 2025, unless extended, after which a subsequent offering period of at least 10 business days will commence for additional share purchases at the same price.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Genmab A/S published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW1001134223-en) on October 21, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment